Re: ATTENTION PFIZER/HOSPIRA READ IMMEDIATELY

Quote
More

We will be immediately importing documentation from Hospira of employment eligibility, which includes auditing I-9 forms and information submitted online that proves all Hospira employees are documented workers. Please include any affirmative action plan documents and background investigation reports
 


















Sorry for the bad news but the Pfizer deal is off. Pfizer got cold feet. Too much tanning salon for Balls and his crew. He fkd it up. Oh well. Back to the same old malignant mindless drones called Hospira management.
 












Wow the Dow plunged 500+ Friday and HSP only loses 12 Cents ! This Stock is STRONG ! It's a good sign for investors BUT Means nothing in terms of employees on their way out
 






If the hospira sale happens on sept 3 like today's press release said, hr was only off by 27 days which is pretty good guesstimate. pfizer originally said second half of year back in

february which would range from july to december a 26 week span .since eu delayed it a week that was a great call and we thank you for narrowing down and posting the internal

email. i intend to ride it out and take any severence or uc benefits mike ball should take care of the peeps who helped him not screw them I sure hope that isn't the case.
 






Mike and Ian will take care of you all....If your position is eliminated,there will be a decent severance package given to you I'm being serious The longer you were employed here, the bigger the package will be Good Luck !
 






anonymous said:
Mike and Ian will take care of you all....If your position is eliminated,there will be a decent severance package given to you I'm being serious The longer you were employed here, the bigger the package will be Good Luck !
Click to expand...

Bullshit. Severance is minimal. Pfizer isn't in the business of caring, only survival. A pitiful company that survives only on the backs of other companies they've destroyed.
 






The typical package offered by HSP is 1 1/2 weeks for every year of service....The maximum You can get is 39 Weeks I'm sure PFE will at least equeal this or possibly sweeten it up...If your position is impacted,you'll know about it within a few months
possibly longer

HR
 
























Anonymous said:
The best case projection is the Hospira/Pfizer deal DOES close as projected and that shareholders would earn the spread A merger agreement is a CONTRACT ! If Pfizer tries to bail without a MAC occurring, Hospira could sue them and demand specific performance Hospira could have a judge/court force Pfizer to do the deal Before merger announcement,Hospira was trading at $65 per share If the deal breaks, the stock will probably end up there If it breaks because of troubling news out of Hospira like accounting problems,then the pre-deal downside is probably a best-case scenario BUT if it breaks due to regulatory problems, it's less
If the deal closes, the spread goes to zero and you make about $2.50 However, if the deal breaks, you end up having to cover around $25, So the risk-to-reward ratio is $25 down to $2.50 up It’s a risk-to-reward ratio of 10:1. As a general rule of thumb a 20:1 risk-to-rewards are reserved for SAFE transactions, so this indicates the market is factoring in some DEAL RISK
The odds of Pfizer NOT closing this deal are very low probably a 2% chance I've seen stranger things happen but I wouldn't hold my breathe for this scenario I'm Soooo tired of battling
the mental midgets on here and NOW, the BAGEL eating legal SHARKS lurking on here
Click to expand...

WOW Ball cashed out $91 Million TODAY.... Mine is a meager 459K WTF !

HR4U
 






Michael Ball, former chief executive officer Hospira Inc., the biggest injectable-drug maker, made $91.1 million on the sale of his company’s shares to Pfizer Inc.

Ball, who had run Lake Forest, Illinois-based Hospira since 2011, had 1.41 million shares and options when Pfizer completed its purchase of the company at $90 a share today, according to a regulatory filing. He spent $36 million to exercise his options, then sold shares valued at $127.1 million, according to data compiled from the filing.
Pfizer agreed in February to buy Hospira, which makes intravenous drugs and devices to deliver them, for $17 billion to bolster its roster of generic medicine.
Neha Wadhwa, a spokeswoman for New York-based Pfizer, declined to comment beyond the filing.

HR
 






Top Bottom
Back
Quote